These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14616422)

  • 1. Population pharmacokinetics of ceftazidime in burn patients.
    Dailly E; Pannier M; Jolliet P; Bourin M
    Br J Clin Pharmacol; 2003 Dec; 56(6):629-34. PubMed ID: 14616422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
    Conil JM; Georges B; Lavit M; Laguerre J; Samii K; Houin G; Saivin S
    Br J Clin Pharmacol; 2007 Jul; 64(1):27-35. PubMed ID: 17324245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
    Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
    Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of imipenem in burn patients.
    Dailly E; Kergueris MF; Pannier M; Jolliet P; Bourin M
    Fundam Clin Pharmacol; 2003 Dec; 17(6):645-50. PubMed ID: 15015709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients.
    Walstad RA; Aanderud L; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(5):543-9. PubMed ID: 3069478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The pharmacokinetics of ceftazidime in the burned patients].
    Zong G; Xiao G; Zhang Y
    Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1994 Sep; 10(5):385-8. PubMed ID: 7712387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration.
    Conil JM; Georges B; Fourcade O; Seguin T; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Mar; 45(3):133-42. PubMed ID: 17416108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.
    Panomvana D; Kiatjaroensin SA; Phiboonbanakit D
    Clin Pharmacokinet; 2007; 46(10):859-66. PubMed ID: 17854235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin pharmacokinetics in patients with severe burn injuries.
    Dolton M; Xu H; Cheong E; Maitz P; Kennedy P; Gottlieb T; Buono E; McLachlan AJ
    Burns; 2010 Jun; 36(4):469-76. PubMed ID: 19875238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
    Yang RH; Rong XZ; Hua R; Zhang T
    Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.
    Kashuba AD; Ballow CH; Forrest A
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1860-5. PubMed ID: 8843294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants.
    Shi ZR; Chen XK; Tian LY; Wang YK; Zhang GY; Dong L; Jirasomprasert T; Jacqz-Aigrain E; Zhao W
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics and Dosing Simulations of Ceftazidime in Chinese Neonates.
    Wang H; Li X; Sun S; Mao G; Xiao P; Fu C; Liang Z; Zheng M; Huang Y; Tang H; Ou R; Yang N; Ling X; Zhao Z
    J Pharm Sci; 2018 May; 107(5):1416-1422. PubMed ID: 29274818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
    Smith PF; Dicenzo R; Forrest A; Shelton M; Friedland G; Para M; Pollard R; Fischl M; DiFrancesco R; Morse GD
    Clin Pharmacokinet; 2005; 44(1):99-109. PubMed ID: 15634033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of ceftazidime after a single intramuscular injection in wild turtles.
    Cerreta AJ; Lewbart GA; Dise DR; Papich MG
    J Vet Pharmacol Ther; 2018 Aug; 41(4):495-501. PubMed ID: 29517112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury.
    Boucher BA; Kuhl DA; Hickerson WL
    Clin Infect Dis; 1992 Feb; 14(2):458-63. PubMed ID: 1554831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.
    Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT
    Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.
    Berkhout J; Visser LG; van den Broek PJ; van de Klundert JA; Mattie H
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1862-6. PubMed ID: 12760859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.